Organization
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
8 abstracts
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Maria Sklodowska-Curie National Research Institute and Oncology Centre (MSCI), Warsaw, Poland, Hospital Clínico San Carlos and IdISSC, Madrid, Spain,
Abstract
Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.Org: Stephenson Cancer Center at the University of Oklahoma, Macquarie University Cancer Institute, Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Hunan Provincial People's Hospital, Changsha, China, Linyi Cancer Hospital,
Abstract
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.Org: University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Division of Medical Oncology, National Cancer Center Singapore and Duke-NUS Medical School, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Oregon Health and Science University,
Abstract
Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.Org: Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY,
Abstract
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.Org: Duke Cancer Institute, Duke University Medical Center, Sarcoma Oncology Center, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Royal Marsden Hospital and Institute of Cancer Research,
Abstract
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,